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Background: Changes in the levels of circulating microRNAs (miRNAs) in the serum of humans and animals have
been detected as a result of infection with a variety of viruses. However, to date, such a miRNA profiling study has
not been conducted for foot-and-mouth disease virus (FMDV) infection.
Methods: The relative abundance of 169 miRNAs was measured in bovine serum collected at three different
phases of FMDV infection in a proof-of-concept study using miRNA PCR array plates.
Results: Alterations in specific miRNA levels were detected in serum during acute, persistent, and convalescent
phases of FMDV infection. Subclinical FMDV persistence produced a circulating miRNA profile distinct from cattle
that had cleared infection. bta-miR-17-5p was highest expressed during acute infection, whereas bta-miR-31 was
the highest during FMDV persistence. Interestingly, miR-1281was significantly down-regulated during both acute
and persistent infection. Cattle that cleared infection resembled the baseline profile, adding support to applying
serum miRNA profiling for identification of sub-clinically infected FMDV carriers. Significantly regulated miRNAs
during acute or persistent infection were associated with cellular proliferation, apoptosis, modulation of the
immune response, and lipid metabolism.
Conclusions: These findings suggest a role for non-coding regulatory RNAs in FMDV infection of cattle. Future
studies will delineate the individual contributions of the reported miRNAs to FMDV replication, determine if this
miRNA signature is applicable across all FMDV serotypes, and may facilitate development of novel diagnostic
applications.
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Foot-and-mouth disease virus (FMDV) is the etiological
agent for foot-and-mouth disease (FMD); one of the
most contagious animal diseases known. FMD targets
both domestic and wild cloven-hoofed animals, and out-
breaks affecting important livestock populations, such as
cattle, sheep, and pigs incur enormous economic, polit-
ical, and social ramifications. Traditional containment
strategies combine mass vaccination with large scale ani-
mal culling. FMDV is represented globally by seven* Correspondence: paul.lawrence@biocogent.com
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types and variants. The virus is the prototypic member
of the Aphthovirus genus of the family Picornaviridae
and possesses a single-stranded positive-sense RNA gen-
ome of approximately 8500 nucleotides (nts), which con-
sists of a large open reading frame (ORF) flanked by 5’
and 3’ non-translated regions (NTRs). The positive-
sense RNA functions as a messenger RNA (mRNA) from
which a single polyprotein is translated and subsequently
proteolyzed into a series of intermediate and mature
viral proteins. The ORF is traditionally sub-divided into
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capsid, whereas the P2 and P3 regions encode the virus
non-structural proteins essential for virus replication.
The 5’ and 3’ NTRs flanking the ORF exhibit multiple
secondary RNA structures, which regulate the stepwise
translation of virus proteins and replication of the RNA
genome. Knowledge obtained from the study of the
molecular biology and pathogenesis of FMDV continues
to be applied to the development of improved vaccines
and anti-viral therapies [1, 2].
RNA interference (RNAi), a process by which mRNA
transcripts are targeted for degradation or translational
repression by short non-coding RNA molecules
(ncRNAs) has been widely studied for its utility as an
anti-viral therapeutic platform. Small interfering RNAs
(siRNAs) are generated when large double-stranded
RNA (dsRNA) molecules are gradually processed into
progressively smaller dsRNA of approximately 20–22
nucleotides in length; and have been investigated as
anti-viral therapeutics [3–5]. In the case of FMDV, siR-
NAs targeted to sequences in the virus genome have
been tested for their capacity to impede the progression
of viral infection with reportedly mixed benefits [6–9]. A
key drawback of siRNA-based anti-viral therapies is the
required complete sequence complementarity between
the siRNA and its cognate RNA target. RNA viruses are
highly mutable, and as such, the accumulation of muta-
tions with each replication cycle diminishes the efficacy
of the siRNA treatment. Additionally, with seven differ-
ent serotypes and multiple subtypes and variants of
FMDV, designing siRNAs that are universally functional
across virus strains would be highly challenging.
In contrast to siRNAs, microRNAs (miRNAs) do not re-
quire perfect complementarity to their target RNA mol-
ecule [10–13], which mitigates the effect of mutations in
the RNA genome and facilitates a similar function across
multiple forms of FMDV. Another key difference between
siRNAs and miRNAs is that siRNAs are generally pro-
duced from exogenous RNA molecules, while miRNAs
are generated from endogenous RNA molecules [12]. In
the normal cellular environment, miRNAs act as key post-
transcriptional regulators of gene expression for a variety
of biological processes including immune response, cell
proliferation, and metabolism [14–16].
Currently, miRNAs are also being explored as poten-
tial bio-markers of infectious disease, particularly miR-
NAs that are detectable in the bloodstream [17–21].
Studies have shown that different viruses generate dis-
tinct expression profiles of circulating miRNA, so much
so that one group was able to distinguish between en-
terovirus 71 and coxsackievirus 16 as the etiological
agents for individual cases of hand-foot-and-mouth dis-
ease [17]. Unfortunately, while greater than 2588 human
miRNAs have been identified, only approximately 798bovine miRNAs have been fully characterized (release
21, June 2014, miRBase.org). Furthermore, while the
miRNA response to several bacterial pathogens has been
examined in cattle, very few studies have been con-
ducted in the context of viral infection [22].
Although still an evolving technology, the information
gained from miRNA profiling investigations has contrib-
uted substantially to efforts for curtailing viral infection.
One strategy has been to incorporate miRNA target
sequences into viral genomes that target host anti-viral
response pathways to contribute to the development of
live attenuated vaccine platforms, which has been
accomplished for vesicular stomatitis virus [23], Japanese
encephalitis virus [24], coxsackievirus A21 [23], and in-
fluenza virus [25, 26]. Contrastingly, some viruses have
exploited the opposite approach, as several DNA viruses
and a few RNA viruses have been identified that harbor
functional miRNA sequences [27–29]. Of relevance to
FMDV, miRNA sequences were identified in the anti-
genome (or negative strand intermediate) of a represen-
tative Picornavirus, hepatitis A virus (HAV), thus
demonstrating that RNA viruses, even those whose repli-
cation cycle is confined to the cytoplasm, can encode
functional miRNAs like their DNA virus counterparts
[28, 29]. Although certainly still controversial, these find-
ings contest the notion that RNA viruses would not en-
code functional miRNAs since interactions with the
cellular miRNA machinery would require: (i) localization
of an RNA virus genome to the nucleus and (ii) that pro-
cessing of the pre-miRNA hairpin would irreparably
damage the virus genome.
An alternative anti-viral miRNA strategy has been to
introduce artificial miRNAs in cell culture or in infected
animals to target specific viral sequences or the mRNA
transcripts of cellular proteins that the virus requires for
an efficient replication cycle. This approach has been
beneficially used in two reported instances involving
FMDV, where artificial miRNAs were constructed that
targeted either the IRES sequence in the 5’ NTR or the
coding sequence for the 3D polymerase [30, 31]. When
these constructs were transfected into cell culture prior
to FMDV infection, replication was significantly im-
peded. In another study, the artificial miRNA sequences
were inserted into the genomic DNA of a cell line, so as
to allow for constitutive expression of the anti-FMDV
miRNAs [32]. However, this failed to protect the cells
from FMDV infection due to inefficient localization of
the anti-FMDV miRNAs to sites of virus replication in
the sub-cellular environment.
This current work comprises a proof-of-concept study
in which the differential regulation of serum miRNAs
was investigated in cattle infected with FMDV serotype
A isolate A24 Cruzeiro. The bovine serum miRNA pro-
file was characterized using quantitative reverse
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plates designed to detect the relative abundance levels of
169 of the bovine miRNAs characterized in the past sev-
eral years (Table 1, Fig. 1c). Serum from uninfected ani-
mals was compared to samples obtained through three
distinct phases of FMDV infection: acute infection (peak
viremia), persistent infection (subclinical persistence of
FMDV in the upper respiratory tract), and convalescent
phase, comprising animals that had successfully cleared
the infection (Fig. 1a, b). Distinct miRNA signatures of
up- and down-regulated miRNAs in circulation in re-
sponse to FMDV infection were detected. The results
obtained from this proof-of-concept study reinforce the
application of this approach to future large scale testing
and the investigation of miRNA signatures for other se-































Panel of 169 established bovine miRNAs that were profiled for differential expressioMethods
Animals
Serum samples used for this investigation were derived
from non-vaccinated animals included in studies investi-
gating the pathogenesis of acute and persistent phases of
FMDV infection in cattle [33, 34]. The cattle used were
~200 kg (kg) Holstein cattle that were 6–8 months old,
and were purchased from Thomas D. Morris Inc.
(Reisterstown, MD). Briefly, cattle were infected with
FMDV serotype A isolate A24 Cruzeiro via intra-
nasopharyngeal (INP) inoculation [35] at a dose of 105
BTID50 (50% infectious doses titrated using bovine
tongue). The INP inoculation method represents a needle-
free “simulated-natural system”, where a volume of inocu-
lum is introduced to the nasopharynx of cattle via a plastic


























bta-miR-218 bta-miR-545-5p bta-let-7 g
bta-miR-221 bta-miR-660 bta-let-7i
n in response to FMDV infection in cattle serum
Fig. 1 Schematic overview of miRNA profiling study. a Serum was collected from three different groups of FMDV-infected cattle: acutely infected
(viremic; 3–4 dpi), persistently infected (“FMDV carriers”; 35 dpi) and convalescent (“non-carriers”; 35 dpi), and were compared to uninfected
controls. Each group comprised serum samples from three animals. b miRNAs were purified from individual serum samples. The purified miRNAs
were reverse transcribed into complementary DNA (cDNA). The cDNA samples were then analyzed by RT-PCR on bovine miRNome miRNA array
plates containing primers to 169 different bovine miRNAs. The results obtained indicated which miRNAs were left unchanged, up-regulated, or
down-regulated in response to FMDV infection. c schematic of the organization of the miRNA PCR array plates utilized in this study
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the Plum Island Animal Disease Center (PIADC) Institu-
tional Animal Care and Use Committee (IACUC) under
protocols: 209-12-R and 209-15-R.
Serum sample collection
Whole blood was collected in serum separation tubes,
which were stored on ice until downstream centrifuga-
tion in the laboratory for harvesting the serum. Theserum was then stored at −70 ° C until ready for subse-
quent laboratory testing. Serum samples for miRNA pro-
filing came from whole blood harvested during acute
infection, which was defined as the day on which peak
viremia occurred (3 or 4 days post-inoculation [dpi];
data not shown). Additional samples were obtained dur-
ing the persistent phase of infection (~35 dpi) from cat-
tle that were defined as either persistently infected
“FMDV carriers”, or from animals that had successfully
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mals. The distinction between FMDV carriers and non-
carriers was made based on detection of FMDV in
oropharyngeal fluids beyond 28 dpi (data not shown)
[34]. Serum collected from cattle prior to inoculation
with FMDV was used as a baseline for comparison with
infected and convalescent animals. Each test group com-
prised sera from three individual animals. Samples used
in this study are listed in Additional file 1: Table S3.
miRNA isolation
miRNAs were harvested from serum samples using the
miRNeasy serum/plasma kit (Qiagen, catalog # 217184)
following manufacturer’s instructions. The miRNA har-
vesting process included the addition of the miRNeasy
serum/plasma spike-in control (Qiagen, catalog #
219610) to facilitate downstream quality control. Ex-
tracted miRNA was immediately used for cDNA
synthesis.
cDNA synthesis
cDNA was generated from purified miRNA using the
miScript II RT (reverse transcriptase) kit purchased from
Qiagen (Catalog # 218160) following manufacturer’s in-
structions. Reaction mixes were incubated at 37 ° C for
60 min, followed by 5 min at 95 ° C, and finally cooled
to 4 ° C. The cDNA samples were then stored at −70 ° C
until subsequent analysis.
miScript miRNA PCR array cow miRNome™ profiler plates
Ninety-six well miRNA PCR array plates for the bovine
miRNome™ were purchased from Qiagen (Catalog #
331221, Product # MIBT-651Z and MIBT-652Z). In
addition to wells containing primers for the miRNA spe-
cies listed in Table 1 and shown in Fig. 1, both array
plates possessed wells containing C. elegans miR-39,
snoRNA, and snRNA for normalization of the data as
well as a reverse transcription control (miRTC) and
positive control for the PCR reaction (PPC).
Reverse transcription quantitative PCR (RT-qPCR)
The cDNA generated in the prior RT step was used as
template material for the downstream RT-qPCR analysis.
The cDNA template was diluted and mixed with the re-
agents provided in the miScript SYBR Green PCR kit
purchased from Qiagen (Catalog # 218076), consisting
of QuantiTect SYBR green master mix and miScript uni-
versal primer. 25 μL of combined template and reagents
was loaded onto Qiagen bovine miRnome™ miScript
miRNA PCR array plates 1 and 2 (Product # MIBT-
651Z and MIBT-652Z). The PCR array plates were ana-
lyzed on ABI 7500 thermal cyclers (Applied Biosystems,
Life Technologies, Foster City, CA) using the following
cycling parameters: an initial activation of the HotStar™Taq DNA polymerase at 95 ° C for 15 min, followed by
40 iterative cycles of 15 s (sec) at 94 ° C, 30 s at 55 ° C,
and 30 s at 70 ° C.
miRNA expression profile analysis
The Ct-values accumulated from the RT-PCR analyses
were analyzed using the Qiagen GeneGlobe (http://
www.qiagen.com/us/shop/genes-and-pathways/data-anal
ysis-center-overview-page/mirna-pcr-array-mirbase-prof
iler-plates-data-analysis-center/) online software plat
form (formerly SABiosciences: pcrdataanalysis.sabioscie
nces.com/mirna/arrayanalysis.php). The quality of the
miRNA extractions, RT reactions and PCR efficiency
were evaluated against internal controls included on
each PCR array plate. The data was normalized using
the “global Ct mean of expressed miRNAs” method pro-
vided in the data analysis platform. Post-normalization
of the Ct values, the fold changes in miRNA expression
in each infected and convalescent sample relative to con-
trol samples was calculated using the ΔΔCt method [36].
The significance of the fold-changes was evaluated using
two-tailed t-tests comparing each test group (acute,
FMDV carrier, and non-carrier) to the uninfected con-
trol group. Significant levels were set at fold change
>1.50 and p-value < 0.05.
Cell culture
LFBK-αvβ6 cells [37, 38] were generously provided by
Dr. Luis Rodriguez (PIADC, ARS, USDA). The cells
were cultured in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% antibiotic/antimycotic (A/A) at 37 ° C in
humidified incubator with 5% CO2.
miRNA mimic transfection and infection
LFBK-αvβ6 cells were grown to approximately 30–40%
confluence and transfected with mimics to miR-17-5p,
miR-1281 (Thermo Scientific, Waltham, MA), a non-
sense negative control miR (miR-NC), a control miR-
342-5p that does not impact FMDV infection, or left
untransfected following the RNAiMAX (Thermo Scien-
tific, Waltham, MA) transfection method (manufac-
turer’s protocol). Forty-eight hours post-transfection, the
transfected cells were inoculated with FMDV A24
Cruzeiro at a multiplicity of infection (MOI) of 10−3 and
allowed to incubate for 24 h. The resulting virus titers
were then determined for the collected samples follow-
ing a previously described protocol [39]. Briefly, each
sample was diluted 10−1 to 10−6 in virus growth medium
(1% FBS, 1% A/A, and 25 mM HEPES in DMEM) and
the dilutions were applied to LFBK-αvβ6 cell mono-
layers, incubated for 1 h at 37 ° C, acid-washed and
rinsed, following by application of gum tragacanth over-
lay. The plates were then incubated overnight at 37 ° C,
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lent in Histochoice fixative (Amersco, Solon, OH). The
plaques were counted and the calculated plaque forming
units (PFU) per milliliter were plotted using Microsoft
Excel (Microsoft Corporation, Redmond, WA).
Results
Differential regulation of miRNAs in serum during acute
FMDV infection
To determine if FMDV infection of cattle (both acute
and persistent) would induce an alteration in the abun-
dance of circulating miRNAs in the serum, cattle were
inoculated in triplicate with FMDV A24 Cruzeiro via the
intra-nasopharyngeal (INP) route [40]. Serum was col-
lected in acutely infected cattle at 3 dpi (viremic) as well
as at 35 dpi in cattle that either cleared the virus (non-
carriers) or became persistently infected with FMDV
(carriers) (Fig. 1a). Serum was also collected from cattle
prior to inoculation with FMDV as a baseline for com-
parison with infected animals. RNA was harvested and
miRNA purified from the samples from which comple-
mentary DNA (cDNA) was generated via reverse tran-
scriptase reaction (Fig. 1b). The resulting cDNAs were
used as templates for RT-qPCR reactions on miRNA
PCR array plates (Qiagen miScript Bovine miRNome)
containing a series of primers unique to 169 character-
ized bovine miRNAs (Table 1) so as to identify miRNAs
showing either up-regulation or down-regulation in the
collected serum samples (Fig. 1c). The triplicate samples
from each experimental set (acute, non-carrier, and car-
rier) were compared against uninfected controls, and
first evaluated for quality of RT reaction and PCR effi-
ciency; for which passing samples were then normalized
against internal standards. Post-normalization, fold
changes in miRNA levels were only accepted that exhib-
ited statistical significance with p-values <0.05 across
triplicate samples, and were only reported if a greater
than 1.50-fold change was detected.
Importantly, to avoid artifacts of technique, there was
no pre-amplification of miRNAs prior to evaluation on
the miRNA PCR arrays, which can potentially artificially
increase levels of background miRNAs. By this ap-
proach, 7 bovine miRNAs were found up-regulated in
serum collected from cattle acutely infected with FMDV
(3–4 dpi) relative to uninfected controls. Raw scores are
shown in Table 2, while volcano plots of log 2 fold
changes in miRNA levels are shown in Fig. 2a. The up-
regulated miRNA species included bta-miR-17-5p, bta-
miR-146a, bta-miR-144, bta-miR-34a, bta-miR-369-3p,
bta-miR-497, and bta-miR-22-5p (Table 2 and Fig. 2a).
The three most up-regulated miRNAs were bta-miR-17-
5p (+35.88 fold increase), bta-miR-146a (+34.36 fold in-
crease), and bta-miR-144 (+28.78 fold increase) (Table 2).
In contrast, three of the measured targets weresignificantly down-regulated during acute FMDV infec-
tion: bta-let-7 g (−1.96 fold decrease), bta-miR-1281
(−2.50 fold decrease), and bta-miR-26b (-3.09 fold de-
crease) (Table 2 and Fig. 2a). Some of the reported func-
tionalities of these miRNA species are detailed in
Table 2 to extrapolate for possible roles in acute FMDV
infection.
Differential regulation of miRNAs in serum during
persistent FMDV infection
The FMDV carrier state is defined by continuous shed-
ding of low quantities of infectious virus in oropharyn-
geal fluids beyond 28 dpi [41, 42]. This persistent phase
of FMDV infection occurs in approximately 50–100% of
FMDV-infected cattle, and is characterized by subclinical
presence of actively replicating FMDV within the naso-
pharyngeal mucosa [34, 43, 44]. In contrast to acute
FMDV infection, the persistent phase of infection is not
associated with a marked local inflammatory reaction or
a detectable systemic anti-viral response [34, 45]. Nine
of the measured miRNAs were significantly up-regulated
in persistently infected FMDV carriers compared to un-
infected controls; and once again, raw scores are shown
in Table 3, while volcano plots of log 2 fold changes in
miRNA levels are shown in Fig. 2c. As shown in the top
portion of Table 3: bta-miR-22-5p, bta-miR-147, bta-
miR-1224, bta-miR-144, bta-miR-497, bta-miR-154a,
bta-miR-17-5p, bta-miR-205, and bta-miR-31, with fold
changes of 2.17, 5.28, 5.69, 23.78, 24.62, 24.05, 40.84,
41.22, and 43.37, respectively. The corresponding vol-
cano plots for the two array plates are shown in Fig. 2c.
Bta-miR-205 was the strongest induced miRNA during
persistent infection. Three miRNAs were significantly
down-regulated in serum from persistently infected cat-
tle: bta-miR-1281, bta-miR-181b, and bta-miR-23b-5p
with fold decreases of 3.41, 2.77, and 2.44, respectively
(Table 3). The strongest down-regulated miRNA, miR-
1281, was also observed to have decreased levels in the
serum collected from acutely infected cattle.
As could be expected, the miRNA expression profile
in cattle that had successfully cleared FMDV infection
was more similar to that of the uninfected controls. In
this cohort of animals, only two miRNAs were differen-
tially expressed compared to the baseline: bta-miR-150
and bta-miR-455-3p, which were down-regulated 1.65
and up-regulated 68.17 fold, respectively (Table 3). Not-
ably, bta-miR-455-3p was the highest up-regulated
miRNA detected in the entire proof-of-concept study;
see outlying miRNA in the far right of the volcano plot
for array plate 2 (Fig. 2b). The non-carrier results
reinforce the viability of this miRNA profiling approach
described in this proof-of-concept study given that virtu-
ally all of the miRNA species have returned to baseline
levels. As mentioned in the previous section, some of
Table 2 Bovine miRNAs up-regulated and down-regulated in cow serum in response to acute FMDV infection
miRNA regulation in Bovine serum during acute FMDV infection
miRNA Fold change p-value Ascribed function Ref
miR-26b −3.09 0.032 □ Role in adipogenesis and adipocyte differentiation
□ Inhibits HBV replication by targeting CHORDC1
□ Inhibits HCV replication in PBMCs
□ Promotes RSV replication by targeting TLR4
□ Tumor suppressor: targets USP9X, PTGS2, CDK8, TAK1, and TAB3
□ [69–76]
miR-1281 −2.50 0.020 □ Lipid metabolism: in dairy cattle, role in adipogenesis □ [77]
let-7 g −1.96 0.024 □ Cellular proliferation: targets lectin-like oxidized low density lipoprotein receptor-1
(LOX), caspase-3, and Aurora-B
□ [78–80]
miR-22-5p +2.73 0.030 □ Tumor suppressor: targets CDK6, SIRT1, and Sp1 □ [81–88]
miR-497 +26.16 0.031 □ Tumor suppressor: targets CCNE1, insulin-like growth factor 1 receptor (IGF-1R),
checkpoint kinase 1 (CHK1), represses eIF4E, E3 ubiquitin ligase
□ [89–93]
miR-369-3p +28.57 0.015 □ Cellular proliferation: targets N-cadherin
□ Down-regulates adipogenic differentiation in mesenchymal stromal cells
□ [94, 95]
miR-34a +28.57 0.015 □ Tumor suppressor: targets CCND1, CDK6, FMNL2 and E2F5; activated by p53
□ Regulates lipid metabolism with HNF4α
□ Immune modulatory: targets IL-6 and IL-8
□ Found in bovine milk
□ [96–101]
miR-144 +28.78 0.015 □ Tumor suppressor: targets CCNE1, ROCK1, ROCK2, EZH2, TIGAR, AKT3, E2F3,
ADAMTS5, ADAM10, RAB14, and c-Met
□ [102–112]
miR-146a +34.36 0.018 □ Tumor suppressor: targets SOS1
□ Up-regulated by HBV X protein
□ Immune modulatory: induced by NF-KB signaling; targets IRAK1 and TRAF6, thus
diminishing pro-inflammatory response from TLR signaling
□ [113–120]
miR-17-5p +35.88 0.038 □ Cellular proliferation: targets SMAD7, FBXO31, E2F1, and c-Myc
□ Repressed HCV infection, inversely correlated with HCV treatment response
□ HIV-1 Tat C modulates NOX2 and NOX4 via miR-17
□ Immune modulatory: suppresses TLR signaling through IL6 and represses
IFN-stimulated MxA expression
□ [121, 122]
List of bovine miRNAs that were observed to be up-regulated and down-regulated in serum samples collected during the acute phase of FMDV infection.
Shown are the miRNA species, the fold-change in expression levels (in ascending order), and the ascribed function from literature searches of cattle
miRNAs and homologous miRNAs from other species with little to no sequence divergence. The miRNAs listed showed a fold-change in expression levels
of greater than 1.50, and had p-values of <0.05
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NAs is described in Table 3, allowing for hypothetical
contributions to be formulated.
Genomic localization of the differentially expressed
miRNAs
To further characterize the miRNAs that were found to
be differentially regulated in response to FMDV infec-
tion, we sought to determine if there was any correlation
between the miRNAs with respect to where their se-
quences map in the Bos taurus genome. To that end, the
miRNAs were queried in the most current version of
miRbase (release 21, June 2014, miRBase.org) for their
chromosomal sequence sites. As shown in Fig. 3, the
encoded sequences of the miRNAs detected in this study
were found scattered across bovine chromosomes: 1, 2,
5, 7, 8, 10, 11, 12, 16, 18, 19, 21, and 22. The only chro-
mosomes in the Bos taurus genome that were associated
with more than one of the identified miRNAs were:
chromosome #8 with bta-miR-23b-5p, bta-miR-31, and
bta-miR-455-3p; chromosome #16 with bta-miR-34a,bta-miR-181b, and bta-miR-205; chromosome #19 with
bta-miR-22-5p, bta-miR-144, and bta-miR-497; and
finally chromosome #21 with bta-miR-154a and bta-
miR-369-3p. The miRBase database was also queried for
whether the gene sequences for the identified miRNAs
were localized to intergenic or intronic regions of the
Bos taurus genome. Eleven of the miRNAs are encoded
in intergenic regions, including: bta-miR-1281, bta-
miR-150, bta-miR-181b, bta-miR-497, bta-miR-144,
bta-miR-34a, bta-miR-154a, bta-miR-146b, bta-miR-
17-5p, bta-miR-205, and bta-miR-31. The remaining 8
miRNAs are encoded within intronic regions: bta-
miR-26b, bta-miR-455-3p, bta-miR-23b-5p, bta-let-7 g,
bta-miR-22-5p, bta-miR-147, bta-miR-369-3p, and bta-
miR-1224. Based on these findings, we concluded that
there was no pattern to where in the bovine genome
the detected miRNAs were expressed.
Cluster analysis of the differentially expressed miRNAs
Many miRNA sequences encoded in the genomes of
various species have been discovered clustered with
Fig. 2 Differentially expressed miRNAs in response to FMDV infection. The expression patterns of 169 distinct bovine miRNAs was evaluated in
serum harvested during three distinct phases of FMDV infection: a acute (viremic) b convalescent “non-carrier” and c persistently infected
“carrier”. Expression levels were compared against serum from uninfected controls and are plotted onto volcano plots with the fold change in
expression on the X-axis and the degree of reproducibility between replicates (p-value) on the Y-axis. Circles: miRNAs with unchanged expression,
down-regulated expression (green), and up-regulated expression (red). miRNAs with significantly regulated expression (fold-change >1.5 and
p-value of <0.05 [or greater than 1.25 by the –log10]) are plotted above the horizontal lines indicated on the volcano plots
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functions [46, 47]. Given that, cluster analysis was
performed on the differentially regulated bovine miR-
NAs detected in this study using two differentsources: miRbase (release 21, June 2014, miRBase.org)
and MetaMirClust [48]. These two databases provided
corroborating data regarding whether the detected
miRNAs were non-clustered or clustered, and what
Table 3 Bovine miRNAs up-regulated and down-regulated in cow serum in response to persistent FMDV infection
miRNA regulation in Bovine serum during persistent FMDV infection
Persistently Infected FMDV Carriers
miRNA Fold change p-value Ascribed function Ref
miR-1281 −3.41 0.004 □ Lipid metabolism: in dairy cattle, role in adipogenesis □ [50]
miR-181b −2.77 0.044 □ Cellular proliferation: targets RASSF1A and NF-KB
□ Immune modulatory: adenylyl cyclase 9 (AC9), antagonistic to IFNα expression
□ [123–126]
miR-23b-5p −2.44 0.047 □ Tumor suppressor: up-regulated by p53, targets mitochondrial glutaminase,
antagonizes c-Myc signaling, and suppresses metastasis
□ Cellular proliferation: targets proline oxidase
□ [127–132]
miR-22-5p +2.17 0.003 □ Tumor suppressor: targets CDK6, SIRT1, and Sp1
□ Circulating miRNA bio-marker for Huntington’s Disease and acute phase
myocardial infarction
□ Involved in neonatal heart development
□ Anti-inflammatory: negatively regulates type I IFN inflammatory cytokine
response
□ [82–86, 88]
miR-147 +5.28 0.039 □ Anti-inflammatory: TLR2, TLR3, and TLR4 stimulate miR-147 expression,
which participates in negative feedback loop to suppress inflammatory
cytokine expression
□ Up-regulated by HCV Genotype-4
□ Tumor suppressor: targets HOXC6 oncogene
□ [133–135]
miR-1224 +5.69 0.042 □ Tumor suppressor: targets CREB1 □ [136]
miR-144 +23.78 0.037 □ Tumor suppressor: targets cyclin E1 (CCNE1), ROCK1, ROCK2, SMAD4, TIGAR,
E2F3, ADAMTS5, ADAM10, RAB14, ZEB1/2, and c-Met
□ [103–112]
miR-154a +24.05 0.039 □ Tumor suppressor: targets E2F5, ZEB2, Wnt5a, Wnt11, TLR2, and HMGA2 □ [137–143]
miR-497 +24.62 0.044 □ Tumor suppressor: targets CCNE1, insulin-like growth factor 1 receptor (IGF-1R),
checkpoint kinase 1 (CHK1), represses eIF4E, E3 ubiquitin ligase
□ [89–92, 144]
miR-17-5p +40.84 0.029 □ Cellular proliferation: targets SMAD7, FBXO31, E2F1, and c-Myc
□ Repressed HCV production, inversely correlated with HCV treatment response
□ HIV-1 Tat C modulates NOX2 and NOX4 via miR-17-5p
□ Immune modulatory: suppresses TLR signaling through IL-6 and represses
IFN-stimulated MxA expression
□ [121, 122]
miR-205 +41.22 0.027 □ De-regulates lipid metabolism by targeting ACSL1
□ Cellular proliferation: targets ZEB1, ZEB2, Ubc13, PTEN, IL13RA2, COL5A2, ADM,
CXCR2, XPO6, SPSB1, FMO5, and PSMF1
□ HBV X protein hyper-methylates promoter of miR-205 to suppress apoptosis
□ [145, 146]
miR-31 +43.37 0.018 □ Cellular proliferation: up-regulated in tumor cells
□ Downstream target genes of miR-31 have an effect on lipid metabolism and
adipogenesis




miR-455-3p +68.17 0.039 □ Tumor suppressor: targets RAF □ [61]
miR-150 −1.65 0.044 □ Immune modulatory: targets MyD88 (key TLR regulator) and CXCR4 □ [147]
List of bovine miRNAs that were observed to be up-regulated and down-regulated in serum samples collected from cattle persistently infected with FMDV (“FMDV
carriers”) and convalescent cattle that had successfully cleared infection (“non-carriers”). Differential miRNA expression is presented relative to uninfected animals.
Shown are the miRNA species, the fold-change in expression levels (in ascending order), and the ascribed function from literature searches of cattle miRNAs and
homologous miRNAs from other species with little to no sequence divergence. The miRNAs listed showed a fold-change in expression levels of greater than 1.50,
and had p-values of <0.05
Stenfeldt et al. Virology Journal  (2017) 14:71 Page 9 of 18miRNAs clustered with them. As shown in Fig. 4, 11
of the miRNAs that were observed to be differentially
regulated in the serum from cattle during FMDV
infection were not clustered with other miRNAs in the
Bos taurus genome. The non-clustered miRNAs included:
let-7 g, bta-miR-26b, bta-miR-150, bta-miR-34a, bta-miR-
146a, bta-miR-147, bta-miR-205, bta-miR-455-3p, bta-
miR-1224, bta-miR-1281, and bta-miR-31. The remaining
8 miRNAs (bta-miR-497, bta-miR-144, bta-miR-181b, bta-miR-22-5p, bta-miR-23b-5p, bta-miR-17-5p, bta-miR-
154a, and bta-miR-369-3p) detected in this study
were found to be clustered. Of these 8, bta-miR-154a
and bta-miR-369-3p were the most heavily clustered
miRNAs, which is why a more stringent cluster dis-
tance was imposed of <3,000 bp apart. These two
miRNAs were also the only two from this study that
were clustered with each other. Similar to the gen-
omic localization of the detected miRNAs, we
Fig. 3 Genomic localization of miRNAs differentially expressed in response to FMDV infection. The genomic localization of the bovine miRNAs
that were found to be differentially expressed in this study were examined on miRbase (current version) for which chromosomes they localized
to in the Bos taurus genome. Bovine chromosomes on which miRNA sequences localized were arrayed numerically with the chromosome size in
base pairs displayed. miRNAs were listed by their numerical designation in red if down-regulated and in green if up-regulated
Stenfeldt et al. Virology Journal  (2017) 14:71 Page 10 of 18concluded that there was no pattern in the clustering
data.
Effect of miR-17-5p and miR-1281 on the progression of
FMDV infection in vitro
At the completion of the miRNA profiling analysis, we
sought to evaluate the individual impact of one of theFig. 4 Cluster analysis of miRNAs differentially expressed in response to FM
whether the differentially expressed miRNAs detected in this study were cl
The miRNAs found to be non-clustered were listed to the right. The miRNA
miRNA species indicated around the circle. With the exception of bta-miR-
sequences for the cluster analysis was set at <10,000 bpup-regulated and one of the down-regulated miRNA
species identified on FMDV infection in a cell culture
system. Of the miRNA species detected, miR-17-5p and
miR-1281 were selected as they were among the 5
miRNA that showed similar differential expression in
two different animal sets: acutely infected cattle (Table 2
and Fig. 2) and persistently infected cattle (Table 3 andDV infection. Two different databases were employed to assess
ustered or non-clustered: miRbase (current version) and MetaMirClust.
s determined to be clustered were shown in circles with clustered
369-3p with a cutoff of <3000 bp, the distance cutoff between miRNA
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fected into LFBK-αvβ6 cells, a cell line commonly used
for FMDV propagation [37, 38]. Two days post-
transfection, cells were infected with FMDV strain A24
Cruzeiro (the same FMDV strain that was used to infect
cattle in the current study). It was hypothesized that the
elevated expression observed for miR-17-5p in serum
samples collected from acutely as well as persistently in-
fected cattle could indicate that this miRNA was either
induced by FMDV infection to benefit virus replication,
or, induced as a consequence of the host response aim-
ing to suppress virus infection. In the in vitro experi-
ment, there was no impairment to virus replication in
cells transfected with miR-17-5p prior to FMDV infec-
tion, and virus titers produced were nearly identical to
that of the negative controls (untransfected cells and
cells transfected non-sense miRNA mimics [miR-NC])
used in the experiment (Fig. 5a).Fig. 5 Effect of miR-17-5p and miR-1281 mimics on FMDV infection in cell
negative controls: untransfected and irrelevant miR-342-5p. Forty-eight hou
Subsequent to infection, the resulting samples were evaluated for virus tite
following the same procedure as miR-17-5p (a). Resulting virus titers are plott
experiments that were performed in duplicate. miR-17-5p was included in the
panel aIn a separate experiment, we investigated the potential
impact of one of the down-regulated miRNAs that was
common to both acutely and persistently infected cattle,
miR-1281, on the progression of FMDV infection
in vitro. As described for miR-17-5p above, mimic mole-
cules of miR-1281 were transfected into LFBK-αvβ6 cells
and 2 days post-transfection, the cells were infected with
FMDV A24 Cruzeiro. In contrast to the findings with
miR-17-5p, the transfection of miR-1281 prior to FMDV
infection had a negative impact on the progression of
FMDV infection confirmed by a 2 to 3 log reduction in
viral titers observed in transfected cells compared to
controls (Fig. 5b). These in vitro findings are consistent
with the results of the in vivo miRNA-profiling study, in
that an invading virus (in this case FMDV) would likely
attempt to induce the down-regulation of miRNAs that
would be detrimental to its replication cycle, while up-
regulating those that would be beneficial.culture. a Cells were transfected with miR-17-5p mimics in parallel with
rs post-transfection, the cells were infected with FMDV A24 Cruzeiro.
rs, which are plotted. b Cells were transfected with miR-1281 mimics
ed as shown. Both panels a and b are representative of two independent
second experimental set in panel b to confirm the non-effect seen in
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In viral disease research, miRNA profiling has become a
topic of considerable interest as researchers search for
cellular targets that can be exploited in order to combat
infection. In the case of FMDV, the sole miRNA profil-
ing study to date was an investigation of the differential
expression of miRNAs in a porcine based cell line in re-
sponse to infection with an isolate of FMDV serotype
Asia1 [49]. The widespread utility of these findings is
somewhat limited given that cell culture is not necessar-
ily reflective of the molecular pathogenesis of the virus
in an in vivo setting. miRNA profiling analysis of tissue,
urine, and serum samples from infected organisms is be-
ing conducted with greater frequency. Using miRNA
RT-qPCR profiling arrays containing 169 characterized
miRNAs found in Bos taurus, we investigated the differ-
ential levels of miRNAs in sera collected from cattle dur-
ing three distinct phases of infection with FMDV
serotype A isolate A24 Cruzeiro, including acute anda
b
Fig. 6 Schematic overview of the general function of the miRNAs found to
infection. a The miRNAs identified in the study that are unique to acute inf
animals (green circle) are shown, as well as those shared between acutely a
were up- or downregulated. b. The functionality of the miRNAs detected c
(orange circle), immune response (blue circle), and lipid metabolism/adipoge
miRNAs exhibited functionality exclusive to one category and which miRNApersistent phases of infection. Moreover, persistent
phase samples were obtained from sub-clinically infected
FMDV carriers as well as convalescent animals that had
successfully cleared the infection. A total of 19 miRNAs
exhibited an altered abundance in serum in response to
FMDV infection. Five of the miRNAs identified with sig-
nificant shifts in circulating levels relative to uninfected
animals were unique to acutely infected cattle (Fig. 6a,
orange circle), seven were only observed in serum from
persistently infected carriers (Fig. 6a, blue circle),
whereas two were specific to convalescent animals
(Fig. 6a, green circle). Of the miRNAs that were signifi-
cantly up- or down-regulated, five were shared between
acutely and persistently infected cattle (bta-miR-17-5p,
bta-miR-144, bta-miR-497, bta-miR-22-5p, and bta-miR-
1281). Mimics of miR-17-5p and miR-1281 were separ-
ately tested for their effect on FMDV replication in cell
culture (Fig. 5). While miR-17-5p had no apparent im-
pact on the progression of FMDV infection, mimics ofbe differentially expressed in cattle serum in response to FMDV
ection (orange circle), persistent infection (blue circle), and convalescent
nd persistently infected cattle. Red and green arrows indicate if targets
ould be separated into three general categories: cellular proliferation
nesis (green circle). A Venn diagram was constructed showing which
s overlapped into more than one of the aforementioned categories
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logs. From these findings, it could be inferred that the
induction of miR-17-5p in vivo might manipulate the
cellular environment such that it favors FMDV replica-
tion, while miR-1281 is down-regulated due to an antag-
onistic effect. Given that miR-1281 mimics impede
FMDV replication and the reported role of miR-1281 in
cattle [50], it seems that the state of lipid homeostasis in
the host plays an important role in the outcome of
FMDV infection regardless of whether it is acute or per-
sistent. A survey of all the predicted target genes of
these two miRNAs using multiple online algorithms
failed to produce a consensus target to be explored in
this current study (see Additional file 2: Table S1).
The previously reported miRNA profile of a porcine
cell line infected with FMDV serotype Asia1 was ob-
tained using high throughput sequencing [49], which
represents the first time such a differential profiling ex-
periment was performed for FMDV. The present study
represents the first miRNA profiling experiment, albeit a
limited small scale proof-of-concept study, using serum
collected from uninfected and infected cattle. This study
also marks the first time this type of analysis was per-
formed for a serotype A FMDV isolate (A24 Cruzeiro)
as well as the first time differentially expressed miRNAs
were examined in the context of persistent FMDV infec-
tion. Four of the miRNAs detected were shared between
the two profiling studies: miR-22-5p, miR-146b, miR-
23b-5p, and miR-369-3p. Notably, these four miRNAs
all participate in the regulation of cell proliferation and
apoptosis. These may also potentially represent four
miRNAs that are distinctive to FMDV infection across
all serotypes, while the targets not shared between these
two studies represent sets of miRNAs that are either
specific to the FMDV strain or the experimental system
(cell culture versus infected cattle). Future profiling
studies with other FMDV serotypes will be necessary to
bring certainty to these suppositions. We also wanted to
examine the differential miRNA profiles in serum from
cattle infected with other viral pathogens; however, we
were unable to find published reports comparable to the
proof-of-concept study described herein. Despite that,
the miRNA profiles generated from human serum
collected from individuals infected with related + ssRNA
viruses (Dengue virus and HCV) showed some dysregu-
lated miRNAs shared with the ones reported for FMDV
here, which included: let-7 g, miR-22-5p, miR-23b-5p,
miR-146a, and miR-497 [51, 52]. Of note, these shared
miRNAs all are reportedly involved in the signaling
pathways involved in cellular proliferation and apoptosis,
from which it can be inferred that these pathways are
important to life cycle of + ssRNA viruses. Potentially,
these shared miRNAs that are differentially regulated in
the serum in response to invasion by + ssRNA virusessuggest that common molecular mechanisms are acti-
vated or suppressed to either combat + ssRNA viruses or
to alter the host environment such to facilitate + ssRNA
virus replication.
There is increased evidence to support the value of the
application of profiling of miRNAs detectable in circula-
tion as biomarkers suggesting the presence and even
prognosis of specific disease conditions. For example,
hand-foot-and-mouth disease (HFMD) results from in-
fection by one of many possible Picornaviruses, and re-
search has demonstrated that each of these viruses
elicits a unique systemic miRNA response that enables
differentiation of the potential causative agents [17].
Thus, it would be of interest to elucidate the signature
miRNA response for FMDV infection, which may be ap-
plicable across all serotypes of FMDV or could be differ-
ent with each of the seven known serotypes and in
different host organisms such as goats, sheep, and pigs.
Similarly, identification of distinct changes in circulating
miRNAs potentially associated with subclinical persist-
ence of FMDV could be of great value for development
of novel diagnostic approaches for disease surveillance.
Furthermore, some of the miRNAs detected in this study
might also serendipitously target regions of the FMDV
genome, and could be potentially adapted as bio-
therapeutic against FMDV similar to recent report with
miR-203a-3p and miR-203a-5p [53]. To briefly explore
that possibility, a bioinformatics analysis was conducted
using two miRNA recognition sequence mapping algo-
rithms (miRmap and ViTa) [54, 55], where the sequence
for the FMDV isolate used in this study was input (A24
Cruzeiro, Accession #AY593768) along with each indi-
vidual miRNA identified herein (see Additional file 3:
Table S2). The miRmap algorithm reported that 6 of the
19 miRNAs dysregulated in bovine serum in response to
FMDV could potentially target different regions of the
FMDV A24 Cruzeiro RNA genome: bta-miR-17-5p, bta-
miR-497, bta-miR-146a, bta-miR-1224, bta-miR-31, and
bta-miR-150. In contrast, the ViTa algorithm found that
more of these miRNAs could potentially target the gen-
ome, adding bta-miR-205, bta-miR-26b, bta-let-7 g, bta-
miR-34a, bta-miR-144, bta-miR-181b, and bta-miR-147
to the list. Future studies with these new miRNA targets
will certainly need to explore the relative stability of the
FMDV genome in the presence of elevated levels of
these select miRNAs.
While approximately 87% of the profiled miRNAs
exhibited no change in circulation levels between unin-
fected and infected animals, roughly 13% were signifi-
cantly up-regulated or down-regulated as a result of
FMDV infection. Of the differentially regulated miRNAs,
16 (bta-miR-23b-5p, let-7 g, bta-miR-22-5p, bta-miR-
1224, bta-miR-144, bta-miR-497, bta-miR-455-3p, bta-
miR-154a, bta-miR-369-3p, bta-miR-26b, bta-miR-34a,
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5p, and bta-miR-31) have previously been described to
play a role in cellular proliferation or apoptosis (Fig. 6b,
orange circle). Nine of the miRNAs (bta-miR-26b, bta-
miR-34a, bta-miR-205, bta-miR-181b, bta-miR-146a,
bta-miR-17-5p, bta-miR-31, bta-miR-150, and bta-miR-
147), have been ascribed immune modulatory functions
(Fig. 6b, blue circle). Also notable is that five of the de-
tected miRNAs (bta-miR-1281, bta-miR-369-3p, bta-
miR-26b, bta-miR-34a, and bta-miR-205) are involved in
adipogenesis or other lipid metabolic pathways (Fig. 6b,
green circle). Interestingly, there were an equivalent
number of immune modulatory miRNAs differentially
expressed between acutely and persistently infected cat-
tle with one down-regulated and three up-regulated.
Only one of the immune modulatory miRNAs was
shared between the two sets: bta-miR-17-5p, which was
significantly upregulated during both acute and persist-
ent FMDV infection. This miRNA has been extensively
studied for its roles in immune modulation as well as
cellular proliferation and apoptosis [56]. Additionally,
miR-17-5p has been implicated in T-cell activation, B-
cell and monocyte maturation as well as with suppres-
sion of TLR signaling and hampering of the IFN
response [16, 57, 58], which are important functions of
the host anti-viral response. These two test groups also
exhibited approximately the same number of miRNAs
associated with cell proliferation and apoptosis with
eight and ten differentially expressed in acutely and per-
sistently infected animals, respectively. Interestingly,
there were two times more lipid metabolism-related
miRNAs with dysregulated expression in acutely infected
cattle, suggesting that modulation of such pathways is
important to active FMDV replication. It is known that
the VP4 structural protein is acylated with myristate
[59]; and more recently, a SILAC screening showed that
LYPLA, which is a known depalmitoylase, is a critical
factor in FMDV infection [60]. It would be expected that
the serum miRNAs of an animal that cleared FMDV
would return to a basal level similar to an uninfected
animal, and consistent with that, the samples obtained
from convalescent cattle exhibited only two dysregulated
miRNAs: one that is immune modulatory (bta-miR-150)
and one that promotes cellular proliferation (bta-miR-
455-3p). In serum from convalescent animals, bta-miR-
150 was marginally down-regulated, possibly indicating a
reduction in immune system activation given that the
FMDV infection was cleared. In strong contrast, bta-
miR-455-3p was the most up-regulated miRNA in all of
the data sets examined in this study. A survey of
published findings on miR-455-3p point toward it being
a potent upstream regulator of multiple signaling
pathways associated with induced cellular proliferation
[61–63]. Since one of the cellular mechanism forcombating a viral infection is the induction of apoptosis
in infected cells, thereby also increasing cellular turn-
over, the augmentation in bta-miR-455-3p expression
may be reflective of the animal reversing those effects
and shutting down those pathways now that FMDV in-
fection has been eliminated. As with the bioinformatics
analysis conducted to identify prospective gene targets
for miR-17-5p and miR-1281, a consensus target gene
for miR-455-3p was not found to further investigate
(Additional file 2: Table S1). However, consistent with
the speculation above, many of the target genes pro-
posed for miR-455-3p were cell cycle regulators and
zinc-finger containing proteins, from which it can be in-
ferred that this single miRNA was regulating multiple
cell survival pathways to facilitate the final stages of
clearing FMDV infection.
It is interesting to note that six of the 19 miRNAs de-
scribed in this study are considerably abundant in cattle
liver: bta-miR-22-5p, bta-miR-150, bta-miR-17-5p, bta-
miR-455-3p, bta-miR-146, and let 7-g [64]; an organ in
which FMDV does not establish infection. However, due
to the substantial blood flow through the liver, large
quantities of FMDV particles will pass through the liver
during high titer viremia. It is unclear if or how FMDV
may be affecting this tissue to possibly stimulate the
secretion of the aforementioned miRNAs into the circu-
lation. However, acute FMDV infection in cattle has
previously been associated with a strong acute phase re-
sponse characterized by significant induction of serum
amyloid A and haptoglobin levels in serum [65]. These
proteins are secreted from the liver in response to a sys-
temic inflammatory reaction [66], which further suggests
that the systemic effect of FMDV infection may affect
hepatic gene expression and protein synthesis. Further
investigation will be required to elucidate the extent and
potential application of these findings.
In conclusion, we have identified several miRNAs that
are elevated or diminished in circulation of cattle that
have been infected with FMDV. Interestingly, unique
miRNA serum signatures were detected for acutely in-
fected and persistently infected cattle. The unique miR-
NAs found in serum from persistently infected cattle
may help determine what cellular pathways are actively
contributing to the development and maintenance of the
“FMDV carrier state”. Characterization of signature
serum miRNAs that are distinct to the FMDV carrier
state could facilitate identification of persistently in-
fected animals in post-outbreak surveillance. Moreover,
the miRNAs described may also be adapted as potential
anti-viral therapeutics as has been attempted with siR-
NAs in the past [6–9, 67, 68]. Further investigations
including increased sample numbers will be needed to
verify the findings of the current proof-of-concept study.
Additional in vitro investigations may provide further
Stenfeldt et al. Virology Journal  (2017) 14:71 Page 15 of 18knowledge of distinct biological functions and potential
therapeutic applications of the bovine miRNAs identified
herein.Conclusions
Perturbations in the circulating levels of miRNAs in the
bloodstream of humans and animals in response to in-
fection can potentially provide diagnostic and prognostic
value. Here, for the first time in a small scale proof-of-
concept study, differentially regulated serum miRNAs
from cattle infected with FMDV at different phases of
infection were reported. Signature circulating miRNAs
were identified for acutely and persistently infected ani-
mals, which could be applied to the development of
diagnostic assays allowing for distinction between carrier
and non-carrier cattle.Additional files
Additional file 1: Table S3. Cattle serum samples used for the miRNA
profiling study. (DOCX 12 kb)
Additional file 2: Table S1. Predicted mRNA targets for indicated
miRNAs. (DOCX 21 kb)
Additional file 3: Table S2. Predicted FMDV genomic targets for
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